Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27952384 | 0.85 | HSD11B1 (0.33) | HSD11B1CCR2LMNAL3MBTL1 | |
| SCHEMBL6199512 | 0.82 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL1448807 | 0.78 | L3MBTL1 (0.44) | L3MBTL1 | |
| SCHEMBL4359857 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL3807203 | 0.78 | CA2 (0.41) | LMNAL3MBTL1 | |
| SCHEMBL5449834 | 0.78 | ALDH1A1 (0.44) | LMNA | |
| SCHEMBL1448415 | 0.77 | CCR2 (0.33) | CCR2L3MBTL1PTGS2 | |
| SCHEMBL2903043 | 0.77 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL3716259 | 0.74 | SMN1; SMN2 (0.46) | HSD11B1L3MBTL1PTGS2 | |
| SCHEMBL17290879 | 0.74 | HTR6 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | claimed |
| EP-2750677-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | claimed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | claimed |
| CN-108473439-B | Pyrazolone derivatives as nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3243515-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3148972-B1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | PROGENRA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018160944-A1 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | PROGENRA, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20120065225-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF | IYER PRAVIN (US) | 2012-03-15 | — | — | US | disclosed |
| US-8084623-B2 | heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents | ROCHE PALO ALTO LLC (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2354124-A2 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | F. Hoffmann-La Roche AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2102157-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008074703-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-5756275-A | IMPROVED IMAGE WHEN USING COUPLER HAVING SUBSTITUENT AT ACTIVE POSITION | FUJI PHOTO FILM CO., LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| CN-1030682-C | Method for preparating N-aryl-3-aryl-4.5-dihydro-IH-pyrazole-l-carboxamides | ROHM AND HASS CORP (US) | 1996-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | TNNI3, PFKP, NOX5 | HSD11B1 935/4885CCR2 3268/4885LMNA 2480/4885 |
| US-20120065225-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF | CNKSR1, RB1, AR | HSD11B1 970/4885CCR2 494/4885LMNA 1012/4885 |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | HSD11B1 710/4885CCR2 3599/4885LMNA 3649/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | HSD11B1 970/4885CCR2 494/4885LMNA 1012/4885 |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | HSD11B1 935/4885CCR2 3268/4885LMNA 2480/4885 |
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | USP7, USP2, USP28 | HSD11B1 4307/4885CCR2 3011/4885LMNA 4515/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | HSD11B1 1332/4885CCR2 800/4885LMNA 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.